USPTO serial 90481364
Serial No. 90481364
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MICHELI, ANGELA M
- Law office
- TTAB
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with Serial No. 90481364?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
HOANG CHI TRUONG
HOANG CHI TRUONG PATENT LAW WORKS LLP310 EAST 4500 SOUTH SUITE 400SALT LAKE CITY, UT 84107UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical assay kits comprised of diagnostic reagents and assays for medical use; Diagnostic kits comprised of medical immunosequencing-based diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing assay kits comprised of diagnostic reagents and assays for medical use; Medical immunosequencing-based assay kits comprised of medical grade reagents and sample plates for detecting cancer, autoimmune disease and infection | ABANDONED | — |
| 042 | Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; medical laboratory immunosequencing-based services for analysis of biological samples | ABANDONED | — |
| 044 | Providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical analysis services for diagnostic and prognostic testing and treatment purposes; providing medical diagnostic and prognostic testing services; providing medical immunosequencing-based testing for cancer, autoimmune disease and infection; consulting services in the field of medical immunosequencing-based testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the diagnosis and treatment of person | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 11, 2022 | MAB4 | ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION | — |
| Jul 9, 2022 | ABN4 | ABANDONMENT - AFTER INTER PARTES DECISION | — |
| Jul 9, 2022 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jul 9, 2022 | OP.S | OPPOSITION SUSTAINED NO. 999999 | — |
| Nov 24, 2021 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Sep 15, 2021 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Sep 7, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 7, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 18, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 2, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 28, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 28, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 28, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 28, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 20, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 26, 2021 | NWAP | NEW APPLICATION ENTERED | — |